$DCTH
Delcath Systems Inc

2016 Q4 Form 10-K Financial Statement

#000156459017005455 Filed on March 29, 2017

View on sec.gov

Income Statement

Concept 2016 Q4 2016 2015 Q4
Revenue $676.0K $1.990M $440.0K
YoY Change 53.64% 13.91% 51.72%
Cost Of Revenue $180.0K $550.0K $100.0K
YoY Change 80.0% 19.05% 25.0%
Gross Profit $500.0K $1.442M $340.0K
YoY Change 47.06% 12.22% 61.9%
Gross Profit Margin 73.96% 72.46% 77.27%
Selling, General & Admin $2.410M $9.434M $2.190M
YoY Change 10.05% -5.74% -22.61%
% of Gross Profit 482.0% 654.23% 644.12%
Research & Development $2.470M $8.448M $2.370M
YoY Change 4.22% 30.25% 253.73%
% of Gross Profit 494.0% 585.85% 697.06%
Depreciation & Amortization $80.00K $305.0K $120.0K
YoY Change -33.33% -50.57% -45.45%
% of Gross Profit 16.0% 21.15% 35.29%
Operating Expenses $4.882M $17.88M $4.570M
YoY Change 6.83% 8.41% 30.57%
Operating Profit -$4.383M -$16.44M -$4.229M
YoY Change 3.64% 8.09% 28.74%
Interest Expense $10.21M $14.33M -$840.0K
YoY Change -1315.48% 21285.07% -354.55%
% of Operating Profit
Other Income/Expense, Net -$14.31M $17.00K -$20.00K
YoY Change 71450.0% 88.89% -300.0%
Pretax Income -$8.490M -$13.93M -$5.090M
YoY Change 66.8% 23.54% 72.54%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$8.486M -$17.97M -$5.095M
YoY Change 66.56% 22.22% 73.01%
Net Earnings / Revenue -1255.33% -903.07% -1157.95%
Basic Earnings Per Share -$1.292K
Diluted Earnings Per Share -$446900B -$1297000B -$458600B
COMMON SHARES
Basic Shares Outstanding 2.197M
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q4 2016 2015 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $4.410M $4.410M $12.61M
YoY Change -65.03% -65.03% -38.4%
Cash & Equivalents $4.409M $4.410M $12.61M
Short-Term Investments
Other Short-Term Assets $28.68M $28.68M $960.0K
YoY Change 2887.5% 2887.5% 332.43%
Inventory $660.0K $660.0K $757.0K
Prepaid Expenses
Receivables $403.0K $400.0K $277.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $34.16M $34.16M $14.60M
YoY Change 133.93% 133.97% -33.53%
LONG-TERM ASSETS
Property, Plant & Equipment $1.083M $1.080M $1.132M
YoY Change -4.33% -4.42% -37.04%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $1.083M $1.080M $1.132M
YoY Change -4.33% -4.42% -37.04%
TOTAL ASSETS
Total Short-Term Assets $34.16M $34.16M $14.60M
Total Long-Term Assets $1.083M $1.080M $1.132M
Total Assets $35.24M $35.24M $15.73M
YoY Change 123.98% 124.03% -33.79%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $594.0K $590.0K $284.0K
YoY Change 109.15% 110.71% -62.03%
Accrued Expenses $3.407M $2.040M $2.243M
YoY Change 51.89% 0.99% -37.75%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $13.34M $13.34M
YoY Change
Total Short-Term Liabilities $36.10M $36.10M $6.312M
YoY Change 471.85% 472.11% 37.94%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $604.0K $630.0K $820.0K
YoY Change -26.34% -23.17% -21.38%
Total Long-Term Liabilities $604.0K $630.0K $820.0K
YoY Change -26.34% -23.17% -85.41%
TOTAL LIABILITIES
Total Short-Term Liabilities $36.10M $36.10M $6.312M
Total Long-Term Liabilities $604.0K $630.0K $820.0K
Total Liabilities $36.73M $36.73M $7.132M
YoY Change 414.99% 415.15% 26.93%
SHAREHOLDERS EQUITY
Retained Earnings -$279.2M -$261.2M
YoY Change 6.88% 5.96%
Common Stock $0.00 $14.00K
YoY Change -100.0% -85.57%
Preferred Stock
YoY Change
Treasury Stock (at cost) $51.00K $51.00K
YoY Change 0.0% 0.0%
Treasury Stock Shares $1.00 $110.00
Shareholders Equity -$1.490M -$1.490M $8.601M
YoY Change
Total Liabilities & Shareholders Equity $35.24M $35.24M $15.73M
YoY Change 123.98% 124.03% -33.79%

Cashflow Statement

Concept 2016 Q4 2016 2015 Q4
OPERATING ACTIVITIES
Net Income -$8.486M -$17.97M -$5.095M
YoY Change 66.56% 22.22% 73.01%
Depreciation, Depletion And Amortization $80.00K $305.0K $120.0K
YoY Change -33.33% -50.57% -45.45%
Cash From Operating Activities -$3.610M -$14.21M -$4.230M
YoY Change -14.66% -13.46% 35.58%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K $258.0K -$40.00K
YoY Change -75.0% 51.76% 0.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 -$1.090M $180.0K
YoY Change -100.0% -705.56%
Cash From Investing Activities -$20.00K -$1.350M $140.0K
YoY Change -114.29% -13600.0% -380.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.470M 7.410M -10.00K
YoY Change -44800.0% -14.43% -102.63%
NET CHANGE
Cash From Operating Activities -3.610M -14.21M -4.230M
Cash From Investing Activities -20.00K -1.350M 140.0K
Cash From Financing Activities 4.470M 7.410M -10.00K
Net Change In Cash 840.0K -8.150M -4.100M
YoY Change -120.49% 5.16% 46.95%
FREE CASH FLOW
Cash From Operating Activities -$3.610M -$14.21M -$4.230M
Capital Expenditures -$10.00K $258.0K -$40.00K
Free Cash Flow -$3.600M -$14.47M -$4.190M
YoY Change -14.08% -12.79% 36.04%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
594000
CY2016Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
18751000
CY2015Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
3785000
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
284000
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3407000
CY2016Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
13343000
CY2015Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
0
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6312000
CY2016 us-gaap Gross Profit
GrossProfit
1442000
CY2015 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
8479000
CY2016 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2016 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2016 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2016 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2016Q2 dei Entity Public Float
EntityPublicFloat
5973172
CY2015Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
0
CY2015Q4 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
0
CY2016Q4 us-gaap Assets Current
AssetsCurrent
34156000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
14601000
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1083000
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1132000
CY2015Q4 us-gaap Assets
Assets
15733000
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
14000
CY2016 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
12780000
CY2016 us-gaap Investment Income Interest
InvestmentIncomeInterest
17000
CY2015 us-gaap Investment Income Interest
InvestmentIncomeInterest
9000
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-17971000
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-14704000
CY2016 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-33000
CY2015 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-28000
CY2016 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18004000
CY2015 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14732000
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-10.59
CY2015 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-14.56
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1696237
CY2015 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1010105
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
18145000
CY2015 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
349000
CY2015 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
308000
CY2015 dcth Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
176000
CY2015 dcth Fair Value Of Warrants Issued Classified As Liability
FairValueOfWarrantsIssuedClassifiedAsLiability
4247000
CY2015 dcth Fair Value Of Warrants Exercised
FairValueOfWarrantsExercised
123000
CY2016 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
161000
CY2016 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
266000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12607000
CY2016Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
403000
CY2015Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
277000
CY2015Q4 us-gaap Inventory Net
InventoryNet
757000
CY2017Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
113457971
CY2016 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
CY2016 dei Trading Symbol
TradingSymbol
DCTH
CY2016Q4 us-gaap Assets
Assets
35239000
CY2016 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2016 dei Document Type
DocumentType
10-K
CY2016 dei Amendment Flag
AmendmentFlag
false
CY2016 dei Document Period End Date
DocumentPeriodEndDate
2016-12-31
CY2016Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
27287000
CY2016Q4 us-gaap Inventory Net
InventoryNet
660000
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
698000
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
960000
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1360239
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
8601000
CY2015Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
269863000
CY2015Q4 us-gaap Liabilities
Liabilities
7132000
CY2015Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
110
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-261217000
CY2015 us-gaap Gross Profit
GrossProfit
1285000
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-8000
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2015Q4 us-gaap Treasury Stock Value
TreasuryStockValue
51000
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1396344
CY2015Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
0
CY2016 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1011000
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6486000
CY2016 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
9434000
CY2015 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
10009000
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
36095000
CY2016Q4 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
699000
CY2016Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.0625
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2243000
CY2015Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
820000
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15733000
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
721000
CY2015 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1757000
CY2016 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
30000
CY2016 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-1000
CY2015 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-15000
CY2016 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-12780000
CY2016 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
649000
CY2016 us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
4435000
CY2016 dcth Fair Value Of Warrants Issued Classified As Liability
FairValueOfWarrantsIssuedClassifiedAsLiability
707000
CY2016 dcth Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
1372000
CY2016 dcth Fair Value Of Warrants Exercised
FairValueOfWarrantsExercised
726000
CY2016 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
161000
CY2015 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
349000
CY2016 us-gaap Restricted Stock Expense
RestrictedStockExpense
266000
CY2015 us-gaap Restricted Stock Expense
RestrictedStockExpense
308000
CY2015 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-564000
CY2016 dcth Interest Income Earned On Money Market And Operating Accounts
InterestIncomeEarnedOnMoneyMarketAndOperatingAccounts
1000
CY2015 dcth Interest Income Earned On Money Market And Operating Accounts
InterestIncomeEarnedOnMoneyMarketAndOperatingAccounts
1000
CY2016 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
14268000
CY2015 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
0
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-260000
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-9000
CY2016 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
138000
CY2015 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
52000
CY2016 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-95000
CY2015 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
420000
CY2016 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1507000
CY2015 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0
CY2016 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-216000
CY2015 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-220000
CY2016 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-14213000
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-16420000
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
258000
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
170000
CY2016 us-gaap Increase In Restricted Cash
IncreaseInRestrictedCash
1087000
CY2015 us-gaap Increase In Restricted Cash
IncreaseInRestrictedCash
0
CY2016 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
CY2015 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
180000
CY2016 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-1345000
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
10000
CY2016 us-gaap Proceeds From Repayments Of Restricted Cash Financing Activities
ProceedsFromRepaymentsOfRestrictedCashFinancingActivities
-26200000
CY2015 us-gaap Proceeds From Repayments Of Restricted Cash Financing Activities
ProceedsFromRepaymentsOfRestrictedCashFinancingActivities
0
CY2016 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
31226000
CY2015 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0
CY2016 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
2383000
CY2015 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
8655000
CY2016 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
7409000
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
8655000
CY2016 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-49000
CY2015 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-107000
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-8198000
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-7862000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20469000
CY2016 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
649000
CY2015 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
0
CY2016 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
28472000
CY2015 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
4247000
CY2016 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
726000
CY2015 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
123000
CY2016 us-gaap Basis Of Accounting
BasisOfAccounting
<div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Basis of Consolidated Financial Statement Presentation</p></td></tr></table></div> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accounting and financial reporting policies of the Company conform to generally accepted accounting principles in the United States of America (GAAP). The preparation of consolidated financial statements in conformity with GAAP requires management to make assumptions and estimates that impact the amounts reported in the Company&#8217;s consolidated financial statements. The consolidated financial statements include the accounts of all entities controlled by Delcath. All significant inter-company accounts and transactions are eliminated.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;">&nbsp;</p></div>
CY2016 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company bases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company&#8217;s consolidated balance sheets and the amount of revenues and expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, the accounting for derivative instrument liabilities, stock-based compensation, valuation of inventory, impairment of long-lived assets, income taxes and operating expense accruals. Such assumptions and estimates are subject to change in the future as additional information becomes available or as circumstances are modified. Actual results could differ from these estimates.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p></div>
CY2016 us-gaap Revenue Recognition Deferred Revenue
RevenueRecognitionDeferredRevenue
<div> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;text-indent:4.53%;">Deferred Revenue</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue on the accompanying consolidated balance sheets includes payment received for product sales to a distributor. When obligations or contingencies remain after the products are shipped, such as training and certifying the treatment centers, revenue is deferred until the obligations or contingencies are satisfied. The Company will recognize the revenue related to product sales when its obligations under the agreement have been satisfied.</p></div>
CY2016 dcth Maximum Period Of Investments With Original Maturities From Date Of Acquisition To Be Cash Equivalents
MaximumPeriodOfInvestmentsWithOriginalMaturitiesFromDateOfAcquisitionToBeCashEquivalents
P3M
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7276369
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1211864
CY2016 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2016Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
346000
CY2015Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
360000
CY2016Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
214000
CY2015Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
251000
CY2016Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
100000
CY2015Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
146000
CY2016Q4 us-gaap Prepaid Insurance
PrepaidInsurance
501000
CY2015Q4 us-gaap Prepaid Insurance
PrepaidInsurance
625000
CY2015Q4 dcth Kits For Clinical Use
KitsForClinicalUse
162000
CY2016Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
197000
CY2015Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
173000
CY2016Q4 dcth Maximum Percentage Of Prepaid Expenses And Other Current Assets
MaximumPercentageOfPrepaidExpensesAndOtherCurrentAssets
0.05
CY2015Q4 dcth Maximum Percentage Of Prepaid Expenses And Other Current Assets
MaximumPercentageOfPrepaidExpensesAndOtherCurrentAssets
0.05
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4886000
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4638000
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3803000
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3506000
CY2016Q4 dcth Accrued Clinical Trial Expenses Current
AccruedClinicalTrialExpensesCurrent
1365000
CY2015Q4 dcth Accrued Clinical Trial Expenses Current
AccruedClinicalTrialExpensesCurrent
692000
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
933000
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
391000
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
286000
CY2015Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
220000
CY2016Q4 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
216000
CY2015Q4 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
219000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
607000
CY2016Q4 dcth Maximum Percentage Of Current Liabilities Accrued
MaximumPercentageOfCurrentLiabilitiesAccrued
0.05
CY2015Q4 dcth Maximum Percentage Of Current Liabilities Accrued
MaximumPercentageOfCurrentLiabilitiesAccrued
0.05
CY2016Q3 us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
0
CY2016Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2016Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
170000000
CY2016Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2013Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
81875
CY2013Q4 dcth Proceeds From Issuance Of Private Placement Gross
ProceedsFromIssuanceOfPrivatePlacementGross
7500000
CY2013Q4 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
6900000
CY2015Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
153750
CY2015Q1 dcth Proceeds From Issuance Of Private Placement Gross
ProceedsFromIssuanceOfPrivatePlacementGross
2600000
CY2015Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
2500000
CY2015Q3 us-gaap Partners Capital Account Units Sale Of Units
PartnersCapitalAccountUnitsSaleOfUnits
600000
CY2015Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
600000
CY2015Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6000000
CY2016Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
425000
CY2016Q4 dcth Proceeds From Issuance Of Private Placement Gross
ProceedsFromIssuanceOfPrivatePlacementGross
1200000
CY2016Q4 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
1100000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
17577
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
32765
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
3121
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
47221
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
5865
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
41356
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
26774
CY2015 dcth Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Exercise Price Per Share
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodExercisePricePerShare
19.04
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
378.08
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
19.04
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
480.16
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
122.40
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
23.95
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
135.77
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
199.31
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y9M29D
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y11M12D
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M24D
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y7M17D
CY2014Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
14116
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
9994
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
1416
CY2015Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
35471
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
15671
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
5218
CY2016Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
14582
CY2014Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
332.16
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
28.48
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
421.60
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
574.72
CY2015Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
22.55
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
26.85
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
19.23
CY2016Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
19.11
CY2016Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
55000
CY2016Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
100000
CY2014Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
53134
CY2015 dcth Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
1091844
CY2015 dcth Class Of Warrant Or Right Exercises In Period
ClassOfWarrantOrRightExercisesInPeriod
13457
CY2015 dcth Class Of Warrant Or Right Expired In Period
ClassOfWarrantOrRightExpiredInPeriod
2833
CY2015Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1128688
CY2016 dcth Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
7031929
CY2016 dcth Class Of Warrant Or Right Exercises In Period
ClassOfWarrantOrRightExercisesInPeriod
499633
CY2016 dcth Class Of Warrant Or Right Expired In Period
ClassOfWarrantOrRightExpiredInPeriod
444964
CY2016Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
7216020
CY2014Q4 dcth Class Of Warrant Or Right Weighted Average Exercise Price
ClassOfWarrantOrRightWeightedAverageExercisePrice
86.69
CY2015 dcth Class Of Warrant Or Right Weighted Average Exercise Price Issued
ClassOfWarrantOrRightWeightedAverageExercisePriceIssued
12.80
CY2015 dcth Class Of Warrant Or Right Weighted Average Exercise Price Exercises In Period
ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod
13.12
CY2015 dcth Class Of Warrant Or Right Weighted Average Exercise Price Expirations In Period
ClassOfWarrantOrRightWeightedAverageExercisePriceExpirationsInPeriod
13.12
CY2015Q4 dcth Class Of Warrant Or Right Weighted Average Exercise Price
ClassOfWarrantOrRightWeightedAverageExercisePrice
16.02
CY2016 dcth Class Of Warrant Or Right Weighted Average Exercise Price Issued
ClassOfWarrantOrRightWeightedAverageExercisePriceIssued
4.80
CY2016 dcth Class Of Warrant Or Right Weighted Average Exercise Price Exercises In Period
ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod
2.75
CY2016 dcth Class Of Warrant Or Right Weighted Average Exercise Price Expirations In Period
ClassOfWarrantOrRightWeightedAverageExercisePriceExpirationsInPeriod
5.68
CY2016Q4 dcth Class Of Warrant Or Right Weighted Average Exercise Price
ClassOfWarrantOrRightWeightedAverageExercisePrice
5.20
CY2014 dcth Class Of Warrant Or Right Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm
P2Y9M11D
CY2015 dcth Class Of Warrant Or Right Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm
P2Y1M28D
CY2016 dcth Class Of Warrant Or Right Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm
P5Y7M2D
CY2016 dcth Number Of Inputs Used For Valuation Of Warrants
NumberOfInputsUsedForValuationOfWarrants
6
CY2014Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
225000
CY2015 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
564000
CY2015Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
3785000
CY2016 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
12780000
CY2016Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
18751000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
952000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
946000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
529000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
428000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
254000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
3109000
CY2016 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
500000
CY2015 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
400000
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-13930000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-11276000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-4040000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-3428000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-17970000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-14704000
CY2016 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
6110000
CY2015 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
4999000
CY2016 dcth Income Tax Rate Reconciliation Net Operating Loss Carryforwards
IncomeTaxRateReconciliationNetOperatingLossCarryforwards
68795000
CY2016 dcth Income Tax Rate Reconciliation State Operating Loss Carryforwards
IncomeTaxRateReconciliationStateOperatingLossCarryforwards
13891000
CY2016 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
4023000
CY2016 us-gaap Income Tax Reconciliation Nondeductible Expense Amortization
IncomeTaxReconciliationNondeductibleExpenseAmortization
767000
CY2015 us-gaap Income Tax Reconciliation Nondeductible Expense Amortization
IncomeTaxReconciliationNondeductibleExpenseAmortization
767000
CY2016 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-2576000
CY2015 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
380000
CY2015Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
83680000
CY2016 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
1141000
CY2015 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
920000
CY2016 dcth Valuation Allowance Deferred Tax Asset Change In Amount Charged To Costs And Expenses
ValuationAllowanceDeferredTaxAssetChangeInAmountChargedToCostsAndExpenses
-75407000
CY2015 dcth Valuation Allowance Deferred Tax Asset Change In Amount Charged To Costs And Expenses
ValuationAllowanceDeferredTaxAssetChangeInAmountChargedToCostsAndExpenses
2649000
CY2016 dcth Income Tax Reconciliation Derivative Charge
IncomeTaxReconciliationDerivativeCharge
4345000
CY2015 dcth Income Tax Reconciliation Derivative Charge
IncomeTaxReconciliationDerivativeCharge
192000
CY2016 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
53000
CY2015 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
674000
CY2016 us-gaap Income Tax Reconciliation Nondeductible Expense Research And Development
IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
250000
CY2015 us-gaap Income Tax Reconciliation Nondeductible Expense Research And Development
IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
199000
CY2016 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
18000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
1386000
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
1279000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
343000
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
633000
CY2016Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
22000
CY2015Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
3796000
CY2016Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
55000
CY2015Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
66000
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
6194000
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
77906000
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
8000000
CY2016Q4 dcth Deferred Income Tax Liabilities Beneficial Conversion Feature
DeferredIncomeTaxLiabilitiesBeneficialConversionFeature
906000
CY2016Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
906000
CY2015Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
0
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
7094000
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
83680000
CY2016Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2015Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2016 us-gaap Deferred Tax Expense From Stock Options Exercised
DeferredTaxExpenseFromStockOptionsExercised
1000000
CY2016Q4 dcth Valuation Allowance Deferred Tax Asset Percentage
ValuationAllowanceDeferredTaxAssetPercentage
1.00
CY2016 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-76600000
CY2015 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
2649000
CY2014Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
81223000
CY2016 dcth Valuation Allowance Deferred Tax Asset Change In Amount Charged To Additional Paid In Capital
ValuationAllowanceDeferredTaxAssetChangeInAmountChargedToAdditionalPaidInCapital
-1854000
CY2016 dcth Valuation Allowance Deferred Tax Asset Change In Amount Charged To Retained Earnings
ValuationAllowanceDeferredTaxAssetChangeInAmountChargedToRetainedEarnings
1010000
CY2016 dcth Valuation Allowance Deferred Tax Asset Change In Amount Charged To Other Comprehensive Income
ValuationAllowanceDeferredTaxAssetChangeInAmountChargedToOtherComprehensiveIncome
-335000
CY2015 dcth Valuation Allowance Deferred Tax Asset Change In Amount Charged To Other Comprehensive Income
ValuationAllowanceDeferredTaxAssetChangeInAmountChargedToOtherComprehensiveIncome
-192000
CY2016Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0

Files In Submission

Name View Source Status
0001564590-17-005455-index-headers.html Edgar Link pending
0001564590-17-005455-index.html Edgar Link pending
0001564590-17-005455.txt Edgar Link pending
0001564590-17-005455-xbrl.zip Edgar Link pending
dcth-10k_20161231.htm Edgar Link pending
dcth-20161231.xml Edgar Link completed
dcth-20161231.xsd Edgar Link pending
dcth-20161231_cal.xml Edgar Link unprocessable
dcth-20161231_def.xml Edgar Link unprocessable
dcth-20161231_lab.xml Edgar Link unprocessable
dcth-20161231_pre.xml Edgar Link unprocessable
dcth-ex231_9.htm Edgar Link pending
dcth-ex311_7.htm Edgar Link pending
dcth-ex312_10.htm Edgar Link pending
dcth-ex321_8.htm Edgar Link pending
dcth-ex322_11.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending